LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SCNX
Scienture Holdings, Inc.
There isn't enough reported data to score SCNX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SCNX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SCNX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SCNX PE Valuation
SCNX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SCNX Forward outlook
There aren't enough analyst estimates for SCNX to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
SCNX Earnings Per Share
SCNX and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
SCNX has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 3,250% for SCNX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SCNX on profitability, with a higher operating margin.
SCNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $56.3K | +449% |
| Q3 2025 | $590.1K | +810% |
| Q4 2024 | $53.1K | -98% |
| Q3 2024 | $64.9K | -97% |
| Q2 2024 | $18.7K | -99% |
| Q4 2023 | $2.4M | -7% |
| Q3 2023 | $2.1M | -14% |
| Q2 2023 | $2.3M | -31% |
SCNX's revenue is recovering but still below its 2020 peak: $343,639 last quarter, up 3250% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -786% | +34029 points |
| Q1 2026 | -6231% | +1709 points |
| Q3 2025 | -739% | +4654 points |
| Q1 2025 | -34815% | N/A |
| Q4 2024 | -7940% | -7676 points |
| Q3 2024 | -5393% | -5352 points |
| Q2 2024 | -7999% | -7983 points |
| Q4 2023 | -263% | -186 points |
SCNX's operating margin was −786% last quarter, up 7154 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with SCNX at down 170%.
SCNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.1M | -$1.1M |
| Q1 2026 | -$2.9M | +$37.2K |
| Q2 2025 | -$2M | -148% |
| Q1 2025 | -$3M | +$7.2M |
| Q4 2024 | -$2.9M | -$1.9M |
| Q2 2024 | $4.2M | +1185% |
| Q1 2024 | -$10.2M | -$9.3M |
| Q4 2023 | -$980.2K | -180% |
SCNX has burned cash in most quarters: −$11M over the past year, against −$10M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SCNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SCNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.5% | -40.6K shares |
| 1 year | +320% | +1.2M shares |
SCNX has 2M diluted shares, up 320% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SCNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -52.5x | Net Cash |
| Q4 2019 | -20.3x | Net Cash |
SCNX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SCNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 5.1 | Oversold |
SCNX's weekly RSI is 28 (oversold) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SCNX PE vs Healthcare Sector
SCNX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has stronger trend alignment. LLY is above 5 of 5 weekly averages versus SCNX above 0 of 4.
SCNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 20% below |
| 20 week MA | $7.26 | 59% below |
| 50 week MA | $9.55 | 68% below |
| 100 week MA | $28.1 | 89% below |
SCNX is in a downtrend: it's below all four of its weekly moving averages, and 89% below its 100-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SCNX on returns for 2026, with the stronger performance.
SCNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $197.5 | $155.0 | -22% |
| 2025 | $155.0 | $12.6 | -92% |
| 2026 YTD | $12.6 | $3.01 | -76% |
SCNX has finished every year since 2024 lower, and it's down 76% so far in 2026.